Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16353
Title: An update on focal therapy for prostate cancer
Authors: Perera, Marlon;Krishnananthan, Nishanth;Lindner, Uri;Lawrentschuk, Nathan L
Issue Date: Nov-2016
EDate: 2016-09-27
Citation: Nature Reviews Urology 2016; 13(11): 641-653
Abstract: Globally, the increased uptake of serum PSA level screening led to an increase in the number of diagnoses of low-risk and intermediate-risk prostate cancer. Traditionally, these patients have been considered for either active surveillance programmes or radical whole-gland therapies, such as prostatectomy or radiotherapy. Focal therapy is an emerging treatment option that involves the focal ablation of prostate cancer with preservation of surrounding healthy tissue. This approach might result in reduced morbidity when compared with whole-gland therapies. In current practice, much controversy surrounds optimal patient selection and preoperative tumour localization strategies. Focal therapy modalities include cryotherapy, high-intensity focused ultrasound, laser ablation, photodynamic therapy, irreversible electroporation, radiofrequency ablation and focal brachytherapy. However, as long-term oncological data for focal therapies are lacking, formal recommendations for its use cannot be made.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16353
DOI: 10.1038/nrurol.2016.177
ORCID: 0000-0001-8553-5618
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/27670618
Type: Journal Article
Subjects: Prostate cancer
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.